Adaptive Biotechnologies Corporation last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $83.9 million (-10.7% year over year) and diluted EPS of $0.02. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
84
-10.7%
|
3
-69.9%
|
0.02
-66.7%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
72
+21.5%
|
-40
-55.3%
|
-0.25
-47.1%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
71
+35.1%
|
-20
+32.9%
|
-0.13
+35.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
72
+51.0%
|
-14
+59.7%
|
-0.09
+61.1%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
94
+102.4%
|
10
+129.8%
|
0.06
+127.3%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
59
+36.3%
|
-26
+44.6%
|
-0.17
+45.2%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
52
+25.2%
|
-30
+37.2%
|
-0.20
+39.4%
|
|
Feb 11, 2025
42 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
47
+3.7%
|
-34
+51.5%
|
-0.23
+52.4%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ADPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WA
- Headquarters
- Seattle, WA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478320
- Former names
- Adaptive TCR Corp (until Jun 2, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.